ArticleFuture science OA2026
Serum HE4 and polymorphisms in MMP9 and MMP13 associated with survival outcome in patients with endometrial carcinoma: a retrospective cohort study and nomogram development.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsEndometrial cancer (EC) is the most common gynecologic malignancy. Identifying prognostic biomarkers can improve outcome prediction and risk stratification. PATIENTS AND
methodsThis study evaluated the prognostic value of serum human epididymis protein 4 (HE4) levels and matrix metalloproteinase (MMP)9/MMP13 gene polymorphisms in EC. A total of 232 surgical EC patients (Jan 2021-Oct 2022) were analyzed. Progression-free survival (PFS) and overall survival (OS) were assessed.
resultsSignificant differences in disease stage, tumor grade, and MMP9 R279Q and MMP13 rs2252070 phenotypes were found between patients with and without disease progression. Similarly, serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), and HE4 also differed significantly between these groups. Significant differences were found between surviving patients and deceased patients in terms of stage (
conclusionsHE4 is a valuable biomarker associated with three-year survival in EC. The phenotypes of MMP9 R279Q and MMP13 rs2252070 may also be associated with three-year PFS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.